88IV - PR Newswire Asia's news - Health Care/Hospital

< Previous page

| Title only | Print

Next page >

Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers TSY-110 is positioned to become the first biosimilar alternative to Roche's Kadcyla ® (ado-trastuzumab emtansine) in major regulated markets. ... 2026-08-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation Memorandum of Understanding establishes a framework for joint development of clinical trial simulation capabilities The partnership unites global clinical operations excellence with advanced digital ... 2026-08-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Asieris Pharmaceuticals Releases 2026 Semi-Annual Report: Core Product Commercialization Delivers, Entering a Harvest Period as the Company Accelerates Its Transition to Biopharma SHANGHAI , Aug. 28, 2026 /PRNewswire/ -- Asieris Pharmaceuticals today released its 2026 Semi-Annual Report, showing comprehensive progress across all business segments. With the gradual realization ... 2026-08-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering SYDNEY , Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies ... 2026-08-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation NANJING, China , Aug. 28, 2026 /PRNewswire/ -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance ... 2026-08-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Tigermed Announces 2026 Interim Results HANGZHOU, China , Aug. 28, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical ... 2026-08-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Singclean 2nd Leaders Summit Charts New Course in Global Aesthetics SHANGHAI , Aug. 28, 2026 /PRNewswire/ -- Hosted within the IMCAS China Conference venue at W Shanghai - The Bund, Singclean 2 nd International Medical Aesthetic Leaders Summit themed "Global ... 2026-08-28T Computer/Electronics Cosmetics & Personal Care Health Care/Hospital Medical Equipment
Beauty Farm 1H2026 Net Profit Surges 40%, Reinforcing Its Industry Leadership 1H2026 Performance Highlights: ... 2026-08-28T Banking/Financial Service Cosmetics & Personal Care Health Care/Hospital
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's HONG KONG , Aug. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved record-high ... 2026-08-28T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
NECA Expands Telehealth Care with New Counselling and Dietitian Support NeuroEndocrine Cancer Australia strengthens free specialist support for patients, carers, and families affected by neuroendocrine cancer. ... 2026-08-28T Health Care/Hospital Medical/Pharmaceuticals

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved